Focus on hard-to-treat diseases increases complexity, while ease of data collection drives non-core data accumulation in the biopharmaceutical sector.
1 report, 1 independent
Updated Aug 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Focus on hard-to-treat diseases increases complexity, while ease of data collection drives non-core data accumulation in the biopharmaceutical sector.